Skip To Main Content

Science at Sanofi

Discover a wide variety of articles, videos, podcasts, accredited courses, applications, conferences and scientific events in different therapeutic areas

Sort by

Filters

Reset
  • Therapeutical Areas
  • Type of Content

The role of Epithelial Barrier Components in AD, insights and implications

This video provides insights into the key components and functions of the epithelial barriers in the skin. It highlights how barrier dysfunction plays a central role in the pathology of atopic dermatitis and emphasizes the importance of transepidermal water loss as a marker of barrier integrity and disease severity.

Practical Approach in Understanding PN Pathophysiology

This video highlights prurigo nodularis (PN) as a systemic disorder driven by neural inflammation and immune dysregulation. Key inflammatory mediators IL-4 and IL-13, along with fibrosis, emerge as central features, emphasizing the need for targeted therapies that address both neural and immune pathways. 

Clinical Indicators of COPD: A GOLD Guidelines Review

This video highlights the key insights from the 2025 Global Initiative for Chronic Obstructive Lung Disease (GOLD) report, presenting a clear, structured, and evidence-based approach to the diagnosis, assessment, and management of COPD.

Adaptive Eating Behaviors in EoE

Pediatric EoE: Indicators for Early Diagnosis and Intervention

Nirsevimab RWD Metanalysis

Long-term Safety and Efficacy of Avalglucosidase Alfa IN Patients with Late-Onset Pompe Disease (NEO-EXT)

Safety and efficacy of Avalglucosidase Alfa versus Alglucosidase Alfa in patints with Late-Onset Pompe Disease (COMET): a phase 3, randomized, multicentral study results

Patient morbidity and mortality in BP

Many factors, including older age and multimorbidity, are associated with mortality in bullous pemphigoid. Read this article to find out more

What is Bullous Pemphigoid

The heterogeneous presentation of bullous pemphigoid may shed light on why patients are underdiagnosed. Read the article to learn more

Treatments and challenges for bullous pemphigoid

Systemic corticosteroids and other immunosuppressants are the current mainstay of therapy but carry risks for patients with bullous pemphigoid. Read this article to find out more

Pathophysiology of Bullous Pemphigoid

In bullous pemphigoid, autoimmunity to BP180 and BP230 is thought to trigger a type 2 inflammatory response. Read this article to find out more